scholarly journals Editorial: don’t forget basic performance measures in the endoscopic assessment of ulcerative colitis

2021 ◽  
Vol 55 (1) ◽  
pp. 129-130
Author(s):  
David Laharie ◽  
Pauline Rivière
Keyword(s):  
Ulcerative Colitis ◽  
Performance Measures ◽  
Basic Performance ◽  
Endoscopic Assessment

Observer agreement in endoscopic assessment of ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A275-A276
Author(s):  
D HOMMES ◽  
M MUL ◽  
G STERRINGA ◽  
F KATE ◽  
G TYTGAT ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Observer Agreement ◽  
Endoscopic Assessment

scholarly journals P225 Using a standardised reporting proforma is associated with improved endoscopic assessment in UC

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S255-S255
Author(s):  
R KADER ◽  
P Middleton ◽  
O Ahmad ◽  
R Dart ◽  
J McGuire ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Site Factors ◽  
Multi Centre Study ◽  
Gi Endoscopy ◽  
Mayo Score ◽  
Chi Squared ◽  
Index Of Severity ◽  
Level Of Training ◽  
Endoscopic Assessment

Abstract Background Repeated endoscopic assessments are an essential part of ulcerative colitis (UC) disease management and current guidelines recommend the use of an endoscopic activity score, either the endoscopic Mayo score or Ulcerative Colitis Endoscopic Index of Severity (UCEIS) as treatment targets. These indices have prognostic value, with endoscopic healing associated with favourable short- and long-term outcomes. This multi-centre study aimed to assess the frequency of using endoscopic disease activity scores in UC patients undergoing lower GI endoscopy. Methods Lower GI endoscopy reports from patients with UC were retrospectively reviewed from 7 sites in London between April and October 2018. Endoscopy reports were assessed based on the BRIDGe endoscopic reporting criteria including the use of Mayo or UCEIS score. The comparison was made between site factors (specialist IBD centres/non-specialist centres, use of reporting proforma), endoscopist speciality (gastroenterology, surgery or nurse endoscopist), level of training (consultant, registrar or nurse endoscopist) and interest in IBD. Chi-squared was used to compare groups. Results 899 lower GI endoscopy reports were reviewed. Mayo or UCEIS was used in 51% of cases (453/899). The use of endoscopic scores were significantly higher in gastroenterologists than in surgeons and nurse endoscopists respectively (401/762 (53%) vs. 22/54 (41%) vs. 30/83 (36%)), and higher in registrar trainees than consultants and nurse endoscopists (175/251 (70%) vs. 248/565 (44%) vs. 30/83 (36%)) and in those with a specialist interest in IBD compared with those without (237/409 (58%) vs. 216/490 (44%), p < 0.0001). The use of endoscopic scores was more frequent in specialist IBD centres than in non-specialist centres (417/728 (58%) vs. 36/172 (21%), p < 0.001). One centre used a reporting proforma which was associated with a significantly higher frequency of score use compared with centres without a proforma (202/260 (78%) vs. 251/639 (39%), p < 0.0001). Conclusion Reporting of endoscopic disease activity using a standardised scoring system occurs in only half of cases from this large multi-centre cohort. Frequency of use is higher in specialist IBD centres and when performed by gastroenterology specialists. Endoscopy reports from a site that used a standardised reporting proforma were significantly more likely to include an endoscopic index as well as a range of other reporting items. This suggests, at least in part, that endoscopy reporting may be optimised by the introduction of a proforma. Integration of a standardised proforma into reporting software would target all endoscopists performing UC endoscopies regardless of speciality, site or IBD interest.

Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis

2014 ◽  
Vol 20 (2) ◽  
pp. 231-239 ◽  
Author(s):  
Guillaume Bouguen ◽  
Barrett G. Levesque ◽  
Suresh Pola ◽  
Elisabeth Evans ◽  
William J. Sandborn
Keyword(s):  
Ulcerative Colitis ◽  
Mucosal Healing ◽  
Endoscopic Assessment

scholarly journals P545 Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S515-S516
Author(s):  
D Rubstov ◽  
P Kakkadasam Ramaswamy ◽  
J Edwards ◽  
D Shukla ◽  
L Willmann ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Remission ◽  
Real World Setting ◽  
Endoscopic Remission ◽  
Endoscopic Score ◽  
Histological Activity ◽  
Maintenance Of Remission ◽  
Histological Remission ◽  
Endoscopic Assessment

Abstract Background Vedolizumab (VDZ) is a gut-specific α4β7 integrin antagonist that has demonstrated efficacy for induction and maintenance of remission in moderate to severe ulcerative colitis (UC). The aim of this study was to assess the rates of histological remission (HR) in a real-world setting and to identify predictors for histological remission. Methods Retrospective cohort study of all UC patients (≥18 years) initiated on VDZ from 2016 to 2020 was completed. Clinical, biochemical, endoscopic and histologic data were collected. All patients received standard induction therapy with VDZ 300 mg IV at Weeks 0, 2, and 6 and maintained on an 8-weekly regimen. Dose was escalated to a every 4-weekly regimen as per physician’s discretion. A 52-week follow-up was completed on all patients. Endoscopic assessment was carried out between 24 and 52 weeks after commencing VDZ. Histological activity was graded as per Nancy index and histological remission was defined as Nancy grade 0. Endoscopic remission was defined as Mayo endoscopic score = 0. Clinical remission was defined as SCCAI ≤ 5. Results A total of 51 patients [55% female, median age 48 years (IQR 35–60)] were included. 16/51 (34%) were anti-TNF exposed. In 30/51 (59%) patients VDZ was combined with steroids at induction and by week 12 steroids were completely tapered in 14/30 (46.7%) patients. At weeks 12, 24 and 52, 89.6%, 87% and 97.5% of patients, respectively, were in clinical remission. 19/37 (51.3%) patients were in endoscopic remission at end of follow up. Median Nancy score prior to commencing VDZ was 3 (IQR: 2–4) and the median Nancy score at end of follow up was 1 (IQR: 0–2). 19/37 (51.3%) patients achieved HR; 3 patients who were in HR at the time of commencement of VDZ remained in HR at the end of follow up. Median baseline faeces calprotectin (FC) was 320 mcg/g (IQR 45–1000) and was similar in patients who achieved HR and those who did not. Median FC at 12 weeks was 155 mcg/g (45–720) and was significantly lower in patients who achieved HR when compared to patients who did not achieve histological remission (45 vs 420, p 0.028). FC at week 12 predicted histological remission (AUC =0.8667). FC ≥ 200mcg/g at week 12 predicted failure to achieve HR with sensitivity 70%, specificity 100%, PPV 100%, NPV 75%, accuracy 84%. Conclusion Vedolizumab is effective in achieving histological remission and FC ≥ 200 mcg/g at week 12 accurately predicts failure to achieve HR in patients treated with VDZ.

Observer agreement in endoscopic assessment of ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A275-A276
Author(s):  
Daniel W. Hommes ◽  
Miranda D.M. Mul ◽  
Gerben J. Sterringa ◽  
Fibo J.W. Kate ◽  
Guido N.J. Tytgat ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Observer Agreement ◽  
Endoscopic Assessment

441 Endoscopic Assessment of Mucosal Activity in Pediatric Ulcerative Colitis: Are Current Methods Reliable?

2014 ◽  
Vol 79 (5) ◽  
pp. AB141
Author(s):  
Thomas D. Walters ◽  
David R. Mack ◽  
James Markowitz ◽  
Anne M. Griffiths ◽  
Brendan Boyle ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Endoscopic Assessment

Use of Chart Audit and Private Feedback to Improve Physician Quality and Performance Measures in Ulcerative Colitis: Preliminary Results

2014 ◽  
Vol 34 ◽  
pp. S39-S40 ◽  
Author(s):  
Laurence Greene ◽  
Kathleen Moreo ◽  
Tamar Sapir ◽  
Katie Stringer ◽  
Gregory D. Salinas ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Performance Measures ◽  
Chart Audit ◽  
Preliminary Results ◽  
And Performance

scholarly journals Automated endoscopic assessment in ulcerative colitis: the next frontier

2021 ◽  
Vol 93 (3) ◽  
pp. 737-739
Author(s):  
Jimmy K. Limdi ◽  
Francis A. Farraye
Keyword(s):  
Ulcerative Colitis ◽  
Endoscopic Assessment
Sign in / Sign up

Export Citation Format

Share Document